GlassScriptPhysician profile
Melisa D Weaver
NPI 1033240056
$3,056.53
in general payments reported to CMS, 2019-2025
27 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $179 · 2023: $294 · 2024: $775 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $548.28 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $286.62 | 2021-2025 | |
| Amgen INC. | $252.82 | 2022-2025 | Evenity, Prolia |
| Corcept Therapeutics | $234.74 | 2024-2025 | Korlym |
| Lilly USA, LLC | $219.15 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $210.22 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $178.92 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $172.25 | 2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $147.17 | 2023-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $98.10 | 2024-2025 | Strensiq |
| Medtronic, INC. | $74.45 | 2022 | |
| Almatica Pharma LLC | $73.15 | 2025 | Teriparatide |
| Shield Therapeutics INC | $70.94 | 2025 | |
| Pfizer INC. | $70.07 | 2024-2025 | |
| Axsome Therapeutics, INC. | $66.36 | 2024-2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $57.61 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.52 | 2021-2024 | Trulance |
| Impel Pharmaceuticals INC. | $42.38 | 2023 | Trudhesa |
| Abbott Laboratories | $40.46 | 2023-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $24.96 | 2025 | |
| Astellas Pharma US INC | $23.04 | 2025 | Veozah |
| Acella Pharmaceuticals, LLC | $22.48 | 2025 | NP Thyroid 60 |
| Rhythm Pharmaceuticals, INC. | $19.36 | 2024 | Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $19.10 | 2021 | |
| Intra-Sana Laboratories | $17.01 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Biohaven Pharmaceuticals, INC. | $15.72 | 2021 | |
| Lundbeck LLC | $14.65 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melisa Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.